Contrarius Investment Management, an investment management company, recently released its third-quarter investor letter for the “Contrarius Global Equity Fund”. The fund’s investor class returned an impressive 30.9% in the September quarter, outperforming the benchmark MSCI World Index and the Average Global Equity Fund. The fund’s investment philosophy is independent of benchmark considerations, leading to portfolios that deviate from the World Index.
In its third-quarter 2025 investor letter, Contrarius Global Equity Fund highlighted Beam Therapeutics Inc. (NASDAQ:BEAM) as one of its top picks. Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines. The stock has shown strong performance, with a one-month return of 19.13% and a 12.26% gain over the last 52 weeks. As of December 29, 2025, Beam Therapeutics Inc. closed at $27.84 per share, with a market capitalization of $2.83 billion.
Contrarius Global Equity Fund expressed optimism about Beam Therapeutics Inc. in its investor letter, citing significant scientific breakthroughs in gene editing, particularly in the area of ‘base editing’ or CRISPR 2.0. The company holds patents for this innovative technology, positioning it as a key player in the gene-editing space.
Despite its potential, Beam Therapeutics Inc. is not among the 30 most popular stocks among hedge funds. However, 27 hedge fund portfolios held shares of the company at the end of the third quarter. While Contrarius Global Equity Fund sees promise in Beam Therapeutics Inc., it also believes that certain AI stocks offer greater upside potential with less downside risk.
For investors seeking opportunities in the AI sector, Contrarius Investment Management recommends exploring undervalued AI stocks that could benefit from current market trends. By identifying AI stocks poised for growth, investors can capitalize on emerging technologies and market dynamics.
Overall, Contrarius Investment Management’s third-quarter investor letter highlights Beam Therapeutics Inc. as a compelling investment opportunity in the gene-editing space. With its innovative technology and strong performance, the company has the potential to deliver significant returns for investors in the coming years.
